Last $34.89 USD
Change Today +0.10 / 0.29%
Volume 2.0M
ZTS On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

zoetis inc (ZTS) Snapshot

Open
$34.77
Previous Close
$34.79
Day High
$34.98
Day Low
$34.69
52 Week High
08/21/14 - $34.98
52 Week Low
04/15/14 - $28.14
Market Cap
17.5B
Average Volume 10 Days
2.9M
EPS TTM
$1.42
Shares Outstanding
501.2M
EX-Date
08/18/14
P/E TM
24.5x
Dividend
$0.29
Dividend Yield
0.81%
Current Stock Chart for ZOETIS INC (ZTS)

zoetis inc (ZTS) Details

Zoetis Inc. is engaged in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals worldwide. It operates through four segments: United States, Europe/Africa/Middle East, Canada/Latin America, and Asia/Pacific. The company offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines that are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy, and dermatology products, as well as reproductive products. The company markets its products to veterinarians and livestock producers through its sales representatives, and technical and veterinary operations specialists. Zoetis Inc. was founded in 1952 and is headquartered in Florham Park, New Jersey.

9,800 Employees
Last Reported Date: 03/26/14
Founded in 1952

zoetis inc (ZTS) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $825.0K
Group President and Executive Vice President
Total Annual Compensation: $605.0K
Executive Vice President and President of U.S...
Total Annual Compensation: $400.0K
President of Research & Development and Execu...
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2013.

zoetis inc (ZTS) Key Developments

Zoetis Inc. Announces Executive Changes

Zoetis Inc. announced the appointment of Paul Herendeen as its new Executive Vice President and Chief Financial Officer (EVP & CFO), completing a leadership transition that began in April. Herendeen has spent the last 16 years in CFO roles at health care companies Warner Chilcott and MedPointe, building on a successful career in finance, banking and private equity partnerships. In his role at Zoetis, Herendeen will oversee the company's Finance and Information Technology (IT) organizations and be part of the Zoetis Executive Team, reporting to CEO Juan Ramón Alaix. He will have responsibility for the financial management, planning and operations for the company's $4.6 billion enterprise. Herendeen replaces former EVP and CFO Rick Passov, who left the company in April. Glenn David, Senior Vice President of Finance Operations, has been serving as Acting CFO in the interim. David will remain at Zoetis and be an integral part of Herendeen's leadership team. Herendeen brings more than 30 years of broad financial experience and leadership to his role at Zoetis, including 16 years as CFO of Warner Chilcott and MedPointe.

Zoetis Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 29, 2014; Revised Earnings Guidance for the Year 2014

Zoetis Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 29, 2014. For the quarter, the company reported revenue of $1,158 million against $1,114 million, income before provision for taxes on income of $200 million against $187 million and net income attributable to company of $136 million or $0.27 per share against $128 million or $0.26 per share in last year. Income from continuing operations was $139 million. On non-GAAP basis, the company reported income before provision for income taxes on income of $268 million compared to $252 million, income from continuing operations of $192 million and net income attributable to the company of $189 million or $0.38 per diluted share compared to $178 million or $0.36 per diluted share for the last year. For the six months, the company reported revenue of $2,255 million against $2,204 million, income before provision for taxes on income of $427 million against $379 million and net income attributable to company of $291 million or $0.58 per share against $268 million or $0.54 per share in last year. Income from continuing operations was $294 million. On non-GAAP basis, the company reported income before provision for income taxes on income of $545 million compared to $504 million, income from continuing operations of $383 million and net income attributable to the company of $380 million or $0.76 per diluted share compared to $357 million or $0.71 per diluted share for the last year. The company narrowed its revenue and adjusted earnings guidance for full year 2014, raising the lower end of previous ranges for both items. The company also revised its reported diluted EPS guidance to account for a one-time charge related to a commercial settlement with customers in Mexico that impacted this quarter. Full-year 2014 guidance includes: Revenue of between $4.675 billion to $4.750 billion. Reported diluted EPS for the full year of between $1.16 to $1.20 per share and adjusted diluted EPS for the full year between $1.50 to $1.54 per share.

Zoetis Inc. to Report Q2, 2014 Results on Aug 05, 2014

Zoetis Inc. announced that they will report Q2, 2014 results on Aug 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZTS:US $34.89 USD +0.10

ZTS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €99.86 EUR +0.70
ImmuCell Corp $4.55 USD -0.03
Merck & Co Inc $58.85 USD -0.63
Valneva SE €4.99 EUR +0.07
Virbac SA €155.00 EUR +1.95
View Industry Companies
 

Industry Analysis

ZTS

Industry Average

Valuation ZTS Industry Range
Price/Earnings 33.1x
Price/Sales 3.8x
Price/Book 13.8x
Price/Cash Flow 29.7x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOETIS INC, please visit www.zoetis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.